Newcastle-based agency Onyx Health has been appointed by biotech company Actigen to provide creative branding work to raise awareness of its services.
The healthcare marketing communications specialist agency was approached by Actigen, which was seeking an agency with scientific knowledge and expertise in pharmaceuticals and life sciences.
The agency will be tasked with providing Actigen with creative branding and communications work, in a bid to showcase its expertise and to establish a strong reputation in the biotech market.
Onyx Health will also work to raise awareness of Actigen’s clinical trial work in rare diseases and the necessity to develop treatment solutions.
Actigen’s work focuses on identifying and developing biological medicines for rare diseases, with a current focus on the development of a drug for a potential breakthrough treatment for the rare disease known as MPS II or Hunters Syndrome.
Actigen’s Managing Director, Michael Braunagel, said: “Onyx Health’s communication support and specialist sector knowledge will help us receive greater recognition for our expertise in rare diseases. GNR-055 is the first therapeutic in our innovative development pipeline, and we hope to be seen and heard for the great work we do, with the help of Onyx Health.”
Onyx Health’s Associate Director, Louise Flintoft (pictured), added: “We are looking forward to working with Actigen to highlight this serious issue and the need for greater clinical research into rare diseases. While the importance of research into rare diseases is becoming increasingly recognised with the recent publication of the Government’s Rare Disease Action plan, more needs to be done.”
